Research for RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel. - aVenture Research
brief.euretina.org
RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel.
RhyGaze AG, based in Basel, Switzerland and Philadelphia, Pa., USA, have announced a Series A financing of USD $86 million for their company, aimed to advance novel gene therapy for optogenetic vision restoration in diseases causing blindness. The investment round was led by GV (Google Ventures), Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund. The company had previously received CHF 10 million seed round in July in 2024, a spin-out